Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Evaluation of Nephure™, and the Reduction of Dietary Oxalate, in Healthy Volunteers

NCT03661216
View directory record Official record
Conditions
Healthy
Interventions
Nephure Oxalate-reducing Enzyme, Placebo
Dietary Supplement · Other
Lead sponsor
Captozyme, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 30, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Stanford Center for Back Pain

NCT02503475
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Real-Time fMRI, CBT or MBSR, Acupuncture
Other · Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 30, 2026, 4:02 PM EDT
Not listed No phase listed Observational

Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft

NCT01746212
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
One-level or two-level anterior lumbar interbody fusion, InQu Bone Graft Extender and Substitute mixed with BMAC, Synthes Spinal Instrumentation
Procedure · Biological · Device
Lead sponsor
Kansas Joint and Spine Institute
Network
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00028665
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carmustine, cisplatin, cyclophosphamide, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

NCT00491530
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ABT-335, rosuvastatin calcium, simvastatin, atorvastatin calcium
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome

NCT03058575
View directory record Official record
Conditions
Gut Microbiome
Interventions
Dietary MACs, Control
Dietary Supplement · Other
Lead sponsor
Access Business Group
Industry
Eligibility
40 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 4:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Whey Protein Supplementation in High School Athletes

NCT05589129
View directory record Official record
Conditions
Body Weight Changes, Athletic Performance, Recovery, Sleep
Interventions
Whey Protein Supplement, Carbohydrate Placebo Control
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Chronic Effects of Fats on Satiety & Energy Needs

NCT03236181
View directory record Official record
Conditions
Overweight, Obesity
Interventions
SFA, MUFA, PUFA, LCn3
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
20 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

NCT03783130
View directory record Official record
Conditions
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions
VRC-HIVRGP096-00-VP, Alum Adjuvant
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use

NCT05345951
View directory record Official record
Conditions
Underage Drinking, Cannabis Use, Drinking, Teen, Drinking, College, College Drinking, Teen Drinking
Interventions
e-PBI
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 19 Years
Enrollment
1,980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Not listed Phase 2 Interventional

Methylene Blue as a Third-line Vasopressor in Septic Shock

NCT04089072
View directory record Official record
Conditions
Septic Shock
Interventions
Methylene Blue, Phenylephrine
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Changing Health and Lifestyle Behaviors of Offspring Following Maternal Bariatric Surgery

NCT05350267
View directory record Official record
Conditions
Obesity, Childhood
Interventions
HALO, Enhanced Standard of Care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

NCT00002571
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®

NCT00929071
View directory record Official record
Conditions
Aging, Pain
Interventions
Evolence, Lidocaine, topical anesthetic
Device · Drug
Lead sponsor
Weinkle, Susan H., M.D.
Individual
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 30, 2026, 4:02 PM EDT
Not yet recruiting Phase 2 Interventional

Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity

NCT07823452
View directory record Official record
Conditions
Obesity & Overweight
Interventions
gut-brain axis (GLP-1)-activating food carbohydrate, starch-based placebo control (commercial maltodextrin)
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 18 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

NCT04847063
View directory record Official record
Conditions
Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer, Atypical Mesothelial Proliferation, Colorectal Cancer
Interventions
Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin, Doxorubicin, Hyperthermic Intraperitonial Chemotherapy, Cisplatin, Mitomycin C
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Early Phase 1 Interventional

Actinic Keratosis Study

NCT02019355
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

NCT00003963
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Interscalene Bupivacaine With Either Liposomal Bupivacaine or Continuous Peripheral Nerve Block for Shoulder Arthroscopy

NCT03816982
View directory record Official record
Conditions
Shoulder Pain
Interventions
Single-injection bupivacaine HCl plus liposomal bupivacaine, Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 30, 2026, 4:02 PM EDT